Association for Molecular Pathology publishes best practice recommendations for clinical HRD testing
Peer-Reviewed Publication
This month, we're turning our attention to Breast Cancer Awareness Month, a time dedicated to increasing awareness, supporting early detection, and highlighting the ongoing research shaping the future of breast cancer treatment and prevention.
Updates every hour. Last Updated: 17-Dec-2025 23:12 ET (18-Dec-2025 04:12 GMT/UTC)
A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within tumours, opening doors for more targeted therapies for patients.
Adding the oncolytic virus immunotherapy pelareorep to paclitaxel chemotherapy warrants further investigation in patients with HR+ HER2- metastatic breast cancer whose disease has progressed after standard first-line treatment, according to PrECOG, LLC, the cancer research group that investigated the combination in the BRACELET-1 (PrECOG 0113) randomized phase 2 trial.
- Development of "dynamic nanomedicines" for efficient delivery of nucleic acid medicines to sentinel lymph nodes.
- Delivering nucleic acid medicines to sentinel lymph nodes, which serve as a checkpoint for cancer metastasis, activates the immune system, helping to suppress cancer metastasis and recurrence.
- Enhancing cancer immunotherapy to make it effective against immunotherapy-resistant tumors.
- Precise size adjustment of nanomedicines (approximately 10 nm) enables delivery to sentinel lymph nodes.
- Precision nanomedicine design via advanced computational modelling.
- Aim to start clinical trials within five years.
- This announcement is part of a research project conducted by Professor Kanjiro Miyata of the Graduate School of Engineering, The University of Tokyo (Visiting Research Scientist at iCONM), in collaboration with iCONM researchers.
New research findings shows that specific bacteria in patients’ gut microbiome correlate with biomarkers that suggest they are at greater risk of heart damage during chemotherapy.
98 women over the age of 60 diagnosed with breast cancer were tested for biomarkers that indicate heart health and their gut bacteria genome was sequenced before chemotherapy.
This study is part of a wider project called CARDIOCARE which will allow the research to expand to a larger study of 600 women to confirm the finding. This work offers the hope that tailored probiotics could be used to help protect women from the heart side-effects of chemotherapy in future.